Colleen Doyle Cooper
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$5.5MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $5.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 28, 2026 | NIH | SBIR Phase I Development of a Novel, Allogeneic Cell Therapy for Difficult to Treat IBD | $356K | CELDARA MEDICAL, LLC |
| Aug 24, 2026 | NIH | SBIR Phase I Precision CAR-NK therapy for VK4-1 autoreactive B cells in autoimmune diseases: advancing treatment with preserved immune function. | $321K | CELDARA MEDICAL, LLC |
| May 26, 2026 | NIH | SBIR Phase II Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma | $1.0M | CELDARA MEDICAL, LLC |
| Dec 24, 2024 | NIH | SBIR Phase II Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma | $1.2M | CELDARA MEDICAL, LLC |
| May 16, 2024 | NIH | SBIR Phase II Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | $998K | CELDARA MEDICAL, LLC |
| Jun 12, 2023 | NIH | SBIR Phase II Preclinical development of an important, broad-spectrum antibody for pandemic influenza | $1000K | CELDARA MEDICAL, LLC |
| Aug 9, 2022 | NIH | SBIR Phase I Development of a broad spectrum antimicrobial to combat chronic lung infection | $301K | CELDARA MEDICAL, LLC |
| Apr 25, 2022 | NIH | SBIR Phase II Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas | $300K | CELDARA MEDICAL, LLC |
Peer ranks
Federal funding#228
Awards as PI#190
Patents#273
Companies
- CELDARA MEDICAL, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.